SG-1906

N/A

Report date: 2023/02/17 10:01:55

Base Information

Drug NameSG-1906
Drug Alias NameSG-1906SG1906
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAnti-CLDN18Anti-Cluster of differentiation 47
TargetsClaudin-18 splice variant 2Cluster of differentiation 47
Therapy Area/IndicationsSolid tumoursNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHangzhou Shangjian Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesZhongsheng Shangjian Biological Medicine (Hangzhou) Co LtdHangzhou Shangjian Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A